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ORIGINAL RESEARCH • NEURORADIOLOGY
Spinal cord injury (SCI) results in permanent sensorimotor deficits and remote neurodegeneration and reorganiza-
tion along the neuroaxis, all of which have strong relation-
ships with clinical outcomes (1,2). These relationships are 
of high clinical relevance because in vivo neuroimaging 
assessing volumetric and microstructural changes of the 
central nervous system might help to improve prediction 
of outcome and stratification of patients in future inter-
ventional trials (3).
To understand biochemical alterations in the atrophied 
cervical cord (1) after chronic SCI, proton MR spectros-
copy is the tool of choice because it allows noninvasive 
characterization of metabolic alterations. The spinal cord 
is one of the most difficult areas within the central nervous 
system to interrogate by using MR spectroscopy because 
of the low signal-to-noise ratio and magnetic field homo-
geneity owing to its deep location and the heterogeneity 
of the surrounding tissue. The quality of spinal cord MR 
spectroscopy has recently improved (4), and this modal-
ity has been applied to the spinal cords of patients with 
different neurologic diseases, including multiple sclerosis 
(5), amyotrophic lateral sclerosis (6), and Friedreich ataxia 
(7). Preliminary results in patients with chronic SCI from 
a different cohort have been published previously (8–10). 
However, to our knowledge, metabolic changes in chronic 
SCI have not yet been systematically investigated.
In this study, we investigated metabolic alterations 
in the atrophied spinal cord above the level of injury at 
vertebral level C2. We assessed the relationship of these 
alterations to spinal cord atrophy, lesion severity, lesion 
level, the completeness of injury, and clinical impairment 
using short-echo proton MR spectroscopy.
Preclinical literature shows demyelination and al-
tered cell and membrane integrity along with activated 
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Purpose: To investigate metabolic changes in chronic spinal cord injury (SCI) by applying MR spectroscopy in the cervical spinal 
cord.
Materials and Methods: Single-voxel short-echo spectroscopic data in study participants with chronic SCI and healthy control sub-
jects were prospectively acquired in the cervical spinal cord at C2 above the level of injury between March 2016 and January 2017 
and were compared between groups. Concentrations of total N-acetylaspartate (tNAA), myo-inositol (mI), total choline-containing 
compounds (tCho), creatine, and glutamine and glutamate complex were estimated from the acquired spectra. Participants were 
assessed with a comprehensive clinical evaluation investigating sensory and motor deficits. Correlation analysis was applied to inves-
tigate relationships between observed metabolic differences, lesion severity, and clinical outcome.
Results: There were 18 male study participants with chronic SCI (median age, 51 years; range, 30–68 years) and 11 male healthy 
control subjects (median age, 45 years; range, 30–67 years). At cervical level C2, tNAA/mI and tCho/mI ratios were lower in par-
ticipants with SCI (tNAA/mI: 226%, P = .003; tCho/mI: 218%; P = .04) than in healthy control subjects. The magnitude of dif-
ference was greater with the severity of cord atrophy (tNAA/mI: R2 = 0.44, P = .003; tCho/mI: R2 = 0.166, P = .09). Smaller tissue 
bridges at the lesion site correlated with lower ratios of tNAA/mI (R2 = 0.69, P = .006) and tCho/mI (R2 = 0.51, P = .03) at the C2 
level. Lower tNAA/mI and tCho/mI ratios were associated with worse sensory and motor outcomes (P , .05).
Conclusion: Supralesional metabolic alterations are observed in chronic spinal cord injury, likely reflecting neurodegeneration, de-
myelination, and astrocytic gliosis in the injured cervical cord. Lesion severity and greater clinical impairment are both linked to the 
biochemical changes in the atrophied cervical cord after spinal cord injury.
© RSNA, 2019
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MRI protocol.—The study was performed with a 3.0-T Phil-
ips MRI unit (Achieva, release 3.2.3; Philips Healthcare, Best, 
the Netherlands) by using a 16-channel sensitivity-encoding 
neurovascular coil (Philips Healthcare) to acquire spectra from 
the cervical cord above the level of injury (Fig 1). MRI mea-
surement sequences included a survey acquisition, anatomic 
acquisitions, and spectroscopic measurements (total examina-
tion duration: 45 minutes).
At the C2 level, we used a T2-weighted image (repetition 
time msec/echo time msec, 3000/120; flip angle, 90°; in-plane 
resolution, 0.5 3 0.5 mm; section thickness, 3.2 mm) to place 
the spectroscopic volume of interest (dimensions: 6 mm 3 9 mm 
3 35 mm, 1.9 mL). We applied the metabolite cycling point-
resolved spatially localized spectroscopy, or PRESS, technique 
(2000–2500 [heartbeat triggered]/30; number of signals ac-
quired, 512; spectral bandwidth, 2000 Hz; readout duration, 512 
msec; imaging time, 35 minutes), as described previously (4). It 
included higher-order shimming, broadband outer volume sup-
pression, and inner volume saturation to minimize the chemi-
cal shift displacement, resulting in a smaller effective voxel size 
(5.5 mm 3 7.5 mm 3 31 mm, 1.3 mL) (shown as a red box 
in Fig 1). We split the spectroscopic acquisition in measurement 
acquisition blocks of 128 or 256 signal averages and readjusted 
the volume of interest on the basis of an updated T2 image to 
minimize participant motion.
At the lesion site, we performed anatomic MRI sequences 
for all tetraplegic (ie, quadriplegic) participants. Each of these 
participants had previously undergone an MRI examination 
performed with a 1.5-T (two participants) or 3.0-T (seven par-
ticipants) Siemens MRI unit (Siemens Healthcare, Erlangen, 
Germany). At the center of the lesion, a sagittal T2-weighted im-
age (for 1.5 T: 4125/106 and flip angle, 150°; for 3.0 T: 3500/84 
and flip angle, 160°) was acquired to assess lesion severity.
MRI Postprocessing
Postprocessing and quantification of spectroscopic 
data.—We reconstructed spectroscopic data using the com-
mercially available MRecon framework (version 3.0.530; 
GyroTools, Zurich, Switzerland) in MATLAB 2014b (ver-
sion 8.3.0.532; MathWorks, Natick, Mass). We used non–
water-suppressed frequency-aligned measurement series 
(4) with truncation and zero filling in the time domain af-
ter 200 msec before quantification by LCModel (6.3–1M) 
(14). Metabolic concentration values are expressed as ratios 
to mI or Cr, because absolute quantification through inter-
nal water referencing in the spinal cord is not reliable be-
cause of the pulsating surrounding cerebrospinal fluid (see 
Fig E1 [online]). The basis set for spectral reconstruction in-
cluded the following metabolites: N-acetylaspartate (NAA), 
N-acetylaspartylglutamate (NAAG), glutamate (Glu), gluta-
mine (Gln), glycerophosphocholine (GPC), phosphocholine 
(PCh), Cr, scyllo-inositol (sI), and mI. Because of strongly 
overlapping resonance lines, we combined the spectra of the 
following metabolites: NAA plus NAAG equals tNAA, GPC 
plus PCh equals tCho, and Gln plus Glu complex equals Glx. 
Following the recommendation of the consensus discussion 
Abbreviations
Cr = creatine, Glx = glutamine and glutamate complex, mI = myo-ino-
sitol, SCA = spinal cord area, SCI = spinal cord injury, SCIM = Spinal 
Cord Independence Measure, tCho = total choline-containing com-
pounds, tNAA = total N-acetylaspartate
Summary
In patients with chronic spinal cord injury, metabolic alterations are 
detected superior to the spinal cord lesion level at MR spectroscopy. 
These alterations likely reflect neurodegeneration, demyelination, and 
astrocytic gliosis in the injured cervical cord.
Implications for Patient Care
 n MR spectroscopy shows biochemical changes above the level of 
spinal cord injury.
 n Lower total N-acetylaspartate-to-myo-inositol and choline-contain-
ing compounds-to-myo-inositol ratios at MR spectroscopy were as-
sociated with worse sensory and motor outcomes (P , .05).
astrocytes (11) remote to the site of traumatic SCI. Patients with 
chronic SCI are thus expected to exhibit altered metabolism in 
the atrophied cervical cord above the level of injury. Owing to 
cell and membrane integrity alteration and demyelination, total 
choline-containing compounds (tCho), creatine (Cr), and total 
N-acetylaspartate (tNAA) may be lower in chronic SCI, whereas 
astrocytic gliosis would result in higher concentrations of myo-
inositol (mI). We therefore investigated three ratios, tNAA/mI, 
tCho/mI, and Cr/mI, with the hypothesis that each metabolite 
would be lower in patients with chronic SCI than in healthy 
control subjects.
Materials and Methods
The local ethics committee of Zurich approved our study 
(KEK-ZH-No.2014-610, PB2016-00126), which was con-
ducted in accordance with the Declaration of Helsinki. All 
participants were informed about the aim and procedure of 
this prospective study prior to measurement and gave written 
informed consent.
Participants
We recruited participants for this study between March 2016 
and January 2017. Inclusion criteria for participants with SCI 
were as follows: (a) chronic traumatic injury (.1 year after 
injury), (b) no other neurologic or mental disorders, and (c) 
ability to undergo MRI. All participants had no preexisting 
neurologic, mental, or medical disorders affecting functional 
outcome. One patient had to be excluded because he did not 
fit into the neurovascular coil.
Experimental Design
Clinical assessments.—Participants with SCI underwent a 
clinical evaluation (E.H., with 5 years of experience) that in-
cluded (a) the International Standards for Neurological Clas-
sification of Spinal Cord Injury protocol (12) for motor, light 
touch, and pinprick scores and (b) the Spinal Cord Indepen-
dence Measure (SCIM) to measure daily life independence 
(13). All participants completed the full protocol.
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Kruskal-Wallis tests followed by pairwise Mann-Whitney U 
tests were performed to assess group differences. The Spearman 
rank correlation test was used to investigate the relationships of 
the metabolite ratios and atrophy, injury level, and clinical out-
come (unadjusted and adjusted for SCA).
The confidence interval was set to 95%, and P , .05 was 
considered to indicate a significant difference. To reduce type II 
error, we did not adjust for multiple comparisons, which poten-
tially increased the rate of type I errors. Age was included in the 
statistical model as a covariate of no interest.
Results
Demographics
We included nine participants with a paraplegic injury (injury 
below neurologic level T1 of the spinal cord) (median age, 48 
years; range, 39–54 years), nine participants with a tetraplegic 
injury (injury above level T2) (median age, 57 years; range, 
30–68 years), and 11 healthy control participants (median age, 
45 years; range, 30–67 years) in the study. There was no signifi-
cant difference in age between any of the groups (P = .22). All 
participants were male; the demographic data are summarized 
in the Table.
All study participants completed the MRI examination and 
clinical assessment. The mean age at injury and the mean num-
ber of years since injury, respectively, were 33 years (range, 14–
48 years) and 19 years (range, 2–29 years) for the paraplegic 
at the MR spectroscopy workshop (Lake Constance, August 
2016), metabolites were included in case the Cramér-Rao 
lower bounds were smaller than 100% (15). All MR spec-
troscopy acquisitions were performed by a trained spectrosco-
pist (P.O.W., with 5 years of experience) without knowledge 
about the clinical status of the participants. Data analysis was 
performed by using an automated processing pipeline.
Postprocessing of MRI data above the level of injury.—The 
cross-sectional spinal cord area (SCA) above the level of injury 
was assessed (by E.H.) on the T2-weighted images using Jim 
6.0 (Xinapse Systems, Aldwincle, England) in all participants 
as previously described (16). In three participants, manual cor-
rection of the surface outline was necessary.
In tetraplegic participants, lesion severity was assessed on the 
midsagittal section of the T2-weighted images by using Jim 6.0 
as previously described (2). At the level of injury, the midsagittal 
anteroposterior lesion width, the midsagittal rostrocaudal lesion 
length, the total midsagittal lesion area, and the thickness of the 
midsagittal ventral and dorsal tissue bridges (total amount of tis-
sue bridges) were quantified (Fig E2 [online]).
Statistical Analysis
For statistical analysis, we used R software, version 3.3.1 (R 
Team, 2016, Vienna), including ggplot2 (17) for visualization. 
Boxplots show data including medians and quartiles; medians 
and ranges are reported in the text.
Figure 1: MR spectroscopic voxel localization and representative spectra. A, Placement of the spectroscopic voxel of interest. A representa-
tive spectrum (background in gray) in a healthy control subject, a participant with paraplegic spinal cord injury (SCI), and a participant with 
tetraplegic SCI. The resulting fits (black) are shown in B. The metabolic components identified in the fit in B are given in red for creatine (Cr), total 
N-acetylaspartate (tNAA), total choline-containing compounds (tCho), myo-inositol (mI), and glutamine and glutamate complex (Glx). ppm = Parts 
per million.
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in participants with tetraplegic SCI. Additional quality measures 
can be found in Table E1 (online).
Metabolic Changes in the Severely Atrophied 
Cervical Spinal Cord
In participants with SCI, cross-sectional SCA at C2 was 17% 
smaller than in control participants (P , .001), with more 
pronounced changes in tetraplegic participants (225%, P , 
.001) than in paraplegic participants (210%, P = .005).
In terms of metabolic changes within this atrophied cord area, 
we found lower tNAA/mI and tCho/mI ratios in participants with 
SCI than in control participants (tNAA/mI: 226%, P = .003; 
tCho/mI: 218%, P = .04) (Fig 2, A, C). This group difference was 
mainly driven by the tetraplegic participant group, which differed 
from the healthy control group (tNAA/mI: 243%, P = .002; 
tCho/mI: 225%, P = .03), whereas paraplegic participants only 
showed a trend toward lower ratios (tNAA/mI: 221%, P = .05; 
tCho/mI: 217%, P = .22) (Fig 2, B, D). Tetraplegic participants 
had lower tNAA/mI ratios than paraplegic participants (228%, 
P = .04), but no difference between subgroups was detected for 
tCho/mI (29%, P = .25). Participants with greater cord atrophy 
had lower levels of tNAA/mI (R2 = 0.44, P = .003) and showed 
the same trend for tCho/mI (R2 = 0.166, P = .09) (Fig 3). No dif-
ferences were found for mI/Cr (P = .07) (Fig E3, A, B [online]).
Relationship between Lesion Characteristics, 
Metabolic Changes at C2 Level, and Clinical 
Outcome
Lesion level was positively associated with tNAA/mI (R2 = 
0.402, P = .005) and showed the same trend for tCho/mI (R2 = 
participants and 41 years (range, 24–60 years) and 12 years 
(range, 2–31 years) for the tetraplegic participants. Paraplegic 
and tetraplegic participants did not significantly differ in terms 
of age at injury (P = .34) or in the number of years since injury 
(P = .42). Eight participants with SCI were classified as being 
in functionally complete condition (American Spinal Injury 
Association Impairment Scale [AIS] score A), and 10 were clas-
sified as being in functionally incomplete condition (AIS score 
B–D) (Table).
Quality of MR Spectroscopy Measurements
Representative spectra acquired in the spinal cord at level C2 
are shown in Figure 1 (the spectroscopic voxel of interest place-
ment is shown in A; measured spectra and fitting results with 
separate metabolite components are shown in B) for a healthy 
control participant, a paraplegic participant, and a tetraplegic 
participant. No measurement block had to be excluded because 
of motion. Valid concentration values could be determined for 
all metabolites in all participants, with the exception of Glx. Glx 
could not be determined and zero was assumed in one healthy 
control subject and one paraplegic participant. No differences in 
metabolite line width (full-width at half-maximum of the NAA 
peak) between healthy control subjects and participants with 
SCI was found (P = .51). The volume of interest between mea-
surement blocks was adjusted in two paraplegic participants, in 
two tetraplegic participants, and in three healthy control partici-
pants because of motion. The signal-to-noise ratios of the spectra 
in the spinal cord were satisfactory; they were a mean of 6 (range, 
4–8) in healthy control participants, a mean of 6 (range, 4–7) in 
participants with paraplegic SCI, and a mean of 5 (range, 4–8) 
Clinical and Epidemiologic Data for All Participants with SCI in the Study
Demographic Data ISNCSCI Findings Outcome Measures
Participant No.
Age at  
Injury (y)
Time Since  
Injury (y) AIS Score Level of Injury Motor Score Light Touch Score Pinprick Score SCIM Score
1 30 13 D C2 75 55 55 74
2 51 6 D C2* 86 56 26 48
3 28 2 A C4 11 23 23 18
4 31 2 A C4 22 31 20 28
5 46 12 C C4 97 112 97 100
6 60 4 D C4 89 79 64 100
7 41 24 A C5 38 22 20 63
8 24 31 B C5 31 68 68 64
9 50 13 D C7 91 110 107 100
10 44 10 A T2 50 39 41 58
11 19 27 A T4 50 71 72 73
12 33 19 A T4 50 51 48 75
13 14 25 B T4 50 78 78 66
14 19 29 B T4 50 50 50 73
15 26 20 A T5 50 48 48 68
16 46 7 A T11 67 87 82 69
17 48 2 D T12 100 94 82 98
18 36 4 D L1 92 106 104 98
Note.—AIS = American Spinal Injury Association Impairment Scale, ISNCSCI = International Standards for Neurological Classification of 
Spinal Cord Injury, SCI = spinal cord injury, SCIM = Spinal Cord Independence Measure.
* Small cyst (,10% of the voxel volume) at C2.
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thermore, a higher tNAA/tCho ratio 
was associated with time since injury 
(R2 = 0.358, P = .009) (Fig 5, A) 
but did not differ between partici-
pants with complete injury and those 
with incomplete injury (P = .69) (Fig 
5, B). In tetraplegic participants, the 
size of midsagittal tissue bridges at the 
lesion site was positively correlated 
with tNAA/mI (R2 = 0.686, P = .006) 
as well as tCho/mI ratios (R2 = 0.506, 
P = .03) above the level of injury (Fig 
E2, B, C). No correlation was found 
between mI/Cr and clinical scores.
The tNAA/mI and Cho/mI ra-
tios were positively associated with 
SCIM score (tNAA/mI: R2 = 0.560, 
P , .001; tCho/mI: R2 = 0.458, 
P = .002) and pinprick score (tNAA/
mI: R2 = 0.353, P = .009; tCho/mI: 
R2 = 0.415, P = .004) (Fig 6, A–D). 
In addition, lower levels of tCho/mI 
were associated with lower light touch 
(R2 = 0.529, P = .001) and motor 
(R2 = 0.531, P = .001) scores (Fig 6, 
E, F). When adjusted for SCA, 
tNAA/mI ratio remained associated 
with SCIM score (R2 = 0.606, P = 
.03), while tCho/mI remained asso-
ciated with light touch (R2 = 0.620, 
P = .03) and motor (R2 = 0.641, P = 
.02) scores.
Discussion
Demyelination, altered cell and 
membrane integrity, and activated as-
trocytes (11) occur remote to the site 
of traumatic spinal cord injury (SCI). 
Patients with chronic SCI may there-
fore exhibit altered metabolism in the 
atrophied cervical cord above the level 
of injury. We found that total tNAA/
mI and tCho/mI ratios were lower in 
the atrophic cervical cord in partici-
pants with chronic SCI, with more 
pronounced changes in tetraplegic 
participants than in paraplegic par-
ticipants. The more caudal the lesion 
level, the higher the ratios of tNAA/
mI and tCho/mI and the closer the 
values to those of healthy control 
subjects. In addition, tNAA/mI and 
tCho/mI ratios were positively associated with sensory and mo-
tor scores, and these associations persisted even when adjusted 
for SCA. This indicates that pathologic processes are reflected 
by metabolite concentrations independently of spinal cord at-
rophy. Therefore, spinal cord spectroscopy above the level of 
0.201, P = .06) (Fig 4, A, B). When we looked only at partici-
pants with complete injury (ie, those with an American Spinal 
Injury Association Impairment Scale score of A), we found as-
sociations between lesion level and both tNAA/mI (R2 = 0.613, 
P = .02) and tCho/mI (R2 = 0.711, P = .01) (Fig 4, C, D). Fur-
Figure 2: Graphs show group differences in metabolic ratios. The group differences in, A, B, 
the ratios of total N-acetylaspartate to myo-inositol (tNAA/mI) and, C, D, the ratios of total choline-
containing compounds to myo-inositol (tCho/mI) are shown for healthy control participants (HC), 
participants with spinal cord injury (SCI), and participants with paraplegic SCI (pSCI) and tetraple-
gic SCI (tSCI). Differences are labeled, and uncorrected P values are noted.
Figure 3: Graphs show spinal cord atrophy and metabolic ratios. The cross-sectional spinal 
cord area at level C2 is shown in participants with spinal cord injury as rank correlations with, A, 
the ratios of total N-acetylaspartate to myo-inositol (tNAA/mI) and, B, total choline-containing com-
pounds to myo-inositol (tCho/mI).
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injury may help improve outcome 
prediction and, potentially, monitor 
treatment effects in clinical trials.
The observed reductions in tNAA/
mI and tCho/mI ratios can be attrib-
uted to either lower levels of NAA 
and choline and/or higher levels of 
mI. NAA is synthesized in the mi-
tochondria of neurons from aspartic 
acid and acetyl coenzyme A (18) and 
is predominantly present in neuro-
nal cell bodies and axons. This sug-
gests that decreased NAA reflects 
a combination of axonal/neuronal 
loss (19) and reduced mitochondrial 
metabolism (20). It has been further 
suggested that acetate (from degrada-
tion of NAA) is used to build lipids 
for maintaining myelination (21). 
Thus, a reduction in NAA might also 
relate to demyelination. In line with 
this, higher mI levels likely indicate 
the presence of activated astrocytes, 
which produce chondroitin sulfate 
proteoglycans as well as keratins, 
which inhibit axonal regeneration 
(22). On the other hand, total cho-
line receives contribution from free 
choline, glycerophosphocholine, and 
phosphocholine, which are precur-
sors of cell membrane synthesis (23) 
and of the neurotransmitter acetyl-
choline (23). Total choline is typically 
increased when there is increased 
membrane turnover or when there is 
inflammation (24). In multiple scle-
rosis, choline is typically increased in 
acute phases of demyelination as the 
degradation of myelin leads to the re-
lease of phosphatidylcholine (25).
Animal studies investigating the 
choline concentration after SCI (26) 
reported highly elevated levels of cho-
line early after injury. These results 
suggest that after SCI, there is an ini-
tial high membrane turnover because 
of cell membrane breakdown and/
or demyelination that levels off over 
time, as there are fewer viable neurons 
capable of undergoing membrane 
turnover.
Next to the observed metabolic 
changes within areas of cord atro-
phy, the tNAA/mI ratio was posi-
tively associated with the severity of 
cord atrophy. This indicates that not 
only do patients with a smaller SCA 
Figure 4: Graphs show lesion proximity and metabolic ratios. The rank correlations of, A, C, 
the neurologic level of injury (C1 to T12) and the ratios of total N-acetylaspartate to myo-inositol 
(tNAA/mI) and, B, D, the neurologic level of injury (C1 to T12) and the ratios of total choline-
containing compounds to myo-inositol (tCho/mI) are shown. The participants’ data are labeled 
according to their American Spinal Injury Association Impairment Scale (AIS) scores from A to D. 
All participants with spinal cord injury are included in A and B, whereas only participants with 
complete injury (ie, AIS score A) are included in C and D.
Figure 5: Graphs show lesion characteristics and metabolic ratios. A, Rank correlation between 
the time since injury (in years) and the ratio of total N-acetylaspartate to total choline-containing 
compounds (tNAA/tCho). B, The ratio of tNAA/tCho is shown for participants with complete injury 
(American Spinal Injury Association Impairment Scale [AIS] score A) versus participants with incom-
plete injury (AIS scores B, C, D, and E).
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improve outcome prediction and patient stratification and 
prove valuable in future clinical trials related to different 
therapy options.
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have more pronounced neurodegeneration 
but also that the structure within the cord 
is altered. Postmortem studies of humans 
with SCI suggest that damaged spinal 
neurons may be partly replaced by fibrous 
connective tissue and collagen (27), which 
might account for this finding. In addi-
tion, we showed that lesion level was posi-
tively associated with tNAA/mI. Thus, the 
larger the initial damage at the lesion site, 
the more axons above the level of injury 
may undergo retro- and anterograde de-
generation. This progressive degeneration 
and change in molecular content are of 
particular importance when treatments are 
investigated, as treatments in patients with 
SCI should ideally start as early as possible 
to prevent further structural damage.
Interestingly, these ratio changes are com-
parable to cervical changes observed in other 
neurodegenerative diseases like multiple 
sclerosis (5), amyotrophic lateral sclerosis 
(6), and Friedreich ataxia (7). For example, 
Carew et al (6) observed 38% lower tNAA/
mI ratios in patients with amyotrophic lateral 
sclerosis and smaller tCho/mI ratios com-
pared with those in control subjects. This is 
comparable to what we observed (226% for 
tNAA/mI and 218% for tCho/mI). Our 
study complements these studies by showing 
for the first time (to our knowledge) that cer-
vical metabolic changes also occur in partici-
pants with SCI. In contrast to other studies, 
we also examined the relationship between 
lesion level and metabolic alterations.
Our study had important limitations. 
Metabolic values are presented as ratios to 
other metabolites and not as absolute values. 
Although absolute quantification is possible 
in the brain by means of referencing the in-
ternal water signal, this is not yet possible in 
the spinal cord because the water reference 
scan in the spinal cord is affected by the sur-
rounding cerebrospinal fluid owing to the 
partial-volume effect and thus does not serve as a reliable and 
valid reference. In addition, our study participant number in 
each group was small. We therefore only included men to ho-
mogenize our groups, but future studies will also include female 
participants. Furthermore, the long protocol examination time 
was a major impediment and still hampers a rapid translation of 
spinal cord MR spectroscopy to clinical diagnostics. However, at 
this stage, proton MR spectroscopy can be used for clinical stud-
ies with respect to therapy response.
In conclusion, we showed that metabolite ratios esti-
mated from short-echo MR spectroscopy correlate more 
strongly with the clinical status of the patient than with 
volumetric measures of the spinal cord alone. This may 
Figure 6: Graphs show metabolic ratios and outcome measures. A, B, Graphs show the 
correlations of the metabolic ratios of total N-acetylaspartate to myo-inositol (tNAA/mI) and, 
C–F, total choline-containing compounds to myo-inositol (tCho/mI) in participants with spinal 
cord injury with outcome measures, including Spinal Cord Independence Measure (SCIM) (in 
A, C ), pinprick score (in B, D), motor score (in E), and light touch score (in F ).
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